Pharmacological Treatment of Dementia

Introduction to Treatment Options

The American College of Physicians and other medical societies recommend cholinesterase inhibitors and memantine as primary pharmacological treatments for dementia, with selection based on dementia type and severity 1, 2

Cholinesterase inhibitors are recommended for mild to moderate Alzheimer's disease, Parkinson's disease dementia, dementia with Lewy bodies, and vascular dementia 2, 3
Combination therapy with memantine and donepezil is recommended for severe Alzheimer's disease in many countries 2
Cholinesterase inhibitors should be discontinued for indications other than Alzheimer's disease, Parkinson's disease dementia, dementia with Lewy bodies, or vascular dementia 4

Treatment decisions should be based on individualized assessment of benefits versus risks 5
Memantine's common side effects include confusion, dizziness, and falls 4
Medication effectiveness should be assessed by monitoring cognition, function, and neuropsychiatric symptoms 2

Consider discontinuing cholinesterase inhibitors after 12 months if there is clinically meaningful worsening despite treatment, no observed benefit, progression to severe/end-stage dementia, intolerable side effects, or poor medication adherence 4, 6, 7
Cholinesterase inhibitors should not be discontinued in patients with clinically meaningful psychotic symptoms, agitation, or aggression until these symptoms have stabilized 7

Deprescribe gradually with dose reduction by 50% every 4 weeks until reaching the initial starting dose 4
After 4 weeks at the starting dose, the medication can be discontinued 4

Non-pharmacological approaches include cognitive training, physical exercise, brain-healthy diet, and reminiscence therapy 2, 3

Palliative care should focus on improving quality of life, maintaining function, and maximizing comfort as dementia progresses 2

Expecting dramatic improvements with medication; benefits are typically modest 1
Using cholinesterase inhibitors for frontotemporal dementia or other non-indicated conditions 4
Continuing medications when there's no evidence of benefit after adequate trial 4
Abrupt discontinuation rather than gradual tapering 4
Overlooking the importance of non-pharmacological interventions 2
Failing to reassess medication effectiveness periodically 2